参考文献/References:
［1］ Benson AB，D’Angelica MI，Abrams T， et al. NCCN guidelines?誖insights： biliary tract cancers， version 2.2023［J］. J Natl Compr Canc Netw， 2023， 21： 694-704.
［2］ Valle JW，Kelley RK，Nervi B，et al. Biliary tract cancer［J］. Lancet， 2021， 397： 428-444.
［3］ European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma［J］. J Hepatol， 2023， 79： 181-208.
［4］ Petrick JL， Campbell PT， Koshiol J， et al. Tobacco， alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangio-carcinoma： the Liver Cancer Pooling Project［J］. Br J Cancer， 2018， 118： 1005-1012.
［5］ Vogel A，Bridgewater J，Edeline J，et al. Biliary tract cancer： ESMO Clinical Practice Guideline for diagnosis，treatment and follow-up［J］. Ann Oncol， 2023， 34： 127-140.
［6］ Sapisochin G， Ivanics T， Heimbach J. Liver transplantation for intrahepatic cholangiocarcinoma： ready for prime time?［J］. Hepatology， 2022， 75： 455-472.
［7］ Riechelmann R，Coutinho AK，Weschenfelder RF，et al. Guideline for the management of bile duct cancers by the brazilian gastrointestinal tumor group［J］. Arq Gastroenterol， 2016， 53： 5-9.
［8］ Waisberg DR，Pinheiro RS，Nacif LS，et al. Resection for intrahepatic cholangiocellular cancer： new advances［J］. Transl Gastroenterol Hepatol， 2018， 3： 60.
［9］ Gomez-Espana MA，Montes AF，Garcia-Carbonero R，et al. SEOM clinical guidelines for pancreatic and biliary tract cancer（2020）［J］. Clin Transl Oncol， 2021， 23： 988-1000.
［10］ Melandro F， Nasto RA， Ginesini M， et al. A narrative review of intrahepatic cholangiocarcinoma： a surgical curative option［J］. Chin Clin Oncol， 2023， 12： 13.
［11］ 杨 安，刘玉娥，申 景． 肝门部胆管癌的介入治疗现状及研究进展［J］． 介入放射学杂志， 2021， 30：312-316．
［12］ 袁文加． 肝内胆管结石合并肝内胆管癌手术切除疗效及预后因素分析［D］． 衡阳：南华大学， 2018．
［13］ Bridgewater J， Galle PR， Khan SA， et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma［J］. J Hepatol， 2014， 60： 1268-1289.
［14］ Kubo S，Shinkawa H，Asaoka Y，et al. Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangio-carcinoma［J］. Liver Cancer， 2022， 11： 290-314.
［15］ Ioffe D， Phull P， Dotan E. Optimal management of patients with advanced or metastatic cholangiocarcinoma： an evidence-based review［J］. Cancer Manag Res， 2021， 13： 8085-8098.
［16］ Green BL，House MG. Nonsurgical approaches to treat biliary tract and liver tumors［J］. Surg Oncol Clin N Am， 2019， 28： 573-586.
［17］ Rimini M，Fornaro L，Lonardi S，et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer： an early exploratory analysis of real-world data［J］. Liver Int，2023，43：1803-1812.
［18］ Cholangiocarcinoma Working Group. Italian clinical practice guidelines on cholangiocarcinoma - part Ⅱ： treatment［J］. Dig Liver Dis， 2020， 52： 1430-1442.
［19］ Benson AB， D’Angelica MI， Abbott DE， et al. Hepatobiliary cancers， version 2.2021， NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw， 2021， 19： 541-565.
［20］ Owen M，Makary MS，Beal EW. Locoregional therapy for intrahepatic cholangiocarcinoma［J］. Cancers（Basel）， 2023， 15：2384.
［21］ Xiang X， Hu D， Jin Z， et al. Radiofrequency ablation vs. surgical resection for small early-stage primary intrahepatic cholangiocar-cinoma［J］. Front Oncol， 2020， 10： 540662.
［22］ 徐中琪，甘 伟，刘 晟，等． 经皮热消融治疗术后复发型肝内胆管细胞癌疗效分析［J］． 介入放射学杂志， 2016， 25：973-976．
［23］ Lee SM， Ko HK， Shin JH， et al. Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma： feasibility and long-term survival［J］. Diagn Interv Radiol， 2020， 26： 45-52.
［24］ Zuo M， Huang J. The history of interventional therapy for liver cancer in China［J］. J Interv Med， 2018， 1： 70-76.
［25］ 许 敏，许丹霞，蒋天安． 不可逆电穿孔技术在肝癌消融治疗中的应用［J］． 介入放射学杂志， 2022， 31：511-514．
［26］ Liu B， Fu D， Fan Y， et al. Irreversible electroporation versus radiofrequency ablation for malignant hepatic tumor： a prospective single-center double-arm trial［J］. J Interv Med， 2022， 5： 89-94.
［27］ Yao R， Hu J， Zhao W， et al. A review of high-intensity focused ultrasound as a novel and non-invasive interventional radiology technique［J］. J Interv Med， 2022， 5： 127-132.
［28］ Hu EY， Bhagavatula S， Shi A， et al. Image-guided ablation of recurrent or unresectable intrahepatic cholangiocarcinoma［J］. J Vasc Interv Radiol， 2023， 34： 1007-1014.
［29］ 中国抗癌协会微创治疗专业委员会．经皮胆管腔内射频消融治疗恶性胆管梗阻中国专家共识（2022年版）［J］． 中华内科杂志， 2022， 61：488-495．
［30］ di Girolamo E，Belli A，Ottaiano A，et al. Impact of endobiliary radiofrequency ablation on survival of patients with unresectable cholangiocarcinoma： a narrative review［J］. Front Oncol， 2023， 13： 1077794.
［31］ Ge N，Wang H，He C，et al. Optimal interventional treatment for liver cancer： HAIC， TACE or iTACE?［J］. J Interv Med， 2023， 6： 59-63.
［32］ 李婉慈，朱晓黎，王万胜，等． 中晚期肝内胆管细胞癌介入治疗的临床疗效分析［J］． 介入放射学杂志， 2016， 25：813-817．
［33］ 金志成，张 齐，朱海东，等． 肝癌根治性切除术后辅助性TACE治疗的研究进展［J］． 中华肝脏病杂志， 2022， 30：340-344．
［34］ Wang J， Xue Y， Liu R， et al. DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma： a prospective clinical study［J］. Front Bioeng Biotechnol， 2022： 1112500.
［35］ Sun T，Zhang W，Chen L，et al. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients［J］. J Cancer， 2022， 13： 1282-1288.
［36］ He M，Jiang N，Yin X，et al. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma： a systematic review and pooled analysis［J］. J Cancer Res Clin Oncol， 2023， 149： 531-540.
［37］ Mosconi C，Cappelli A，Ascanio S，et al. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocar-cinoma［J］. Future Oncol， 2017， 13： 1301-1310.
［38］ Buettner S，Braat AJAT，Margonis GA，et al. Yttrium-90 radioem-bolization in intrahepatic cholangiocarcinoma： a multicenter retrospective analysis［J］. J Vasc Interv Radiol， 2020， 31： 1035-1043.e2.
［39］ Paprottka KJ， Galie F， Ingrisch M， et al. Outcome and safety after 103 radioembolizations with yttrium-90 resin microspheres in 73 patients with unresectable intrahepatic cholangiocar-cinoma： an evaluation of predictors［J］. Cancers（Basel）， 2021， 13： 5399.
［40］ Chan SL， Chotipanich C， Choo SP， et al. Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholan-giocarcinoma： a phase 2 single-arm multicenter clinical trial［J］. Liver Cancer， 2022， 11： 451-459.
［41］ Schartz DA， Porter M， Schartz E， et al. Transarterial yttrium-90 radioembolization for unresectable intrahepatic cholangiocar-cinoma： a systematic review and meta-analysis［J］. J Vasc Interv Radiol ， 2022， 33： 679-686.
［42］ Massani M， Bonariol L， Stecca T. Hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma， a comprehensive review［J］. J Clin Med， 2021， 10： 2552.
［43］ Cai Z， He C， Zhao C， et al. Survival comparisons of hepatic arterial infusion chemotherapy with mFOLFOX and transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma［J］. Front Oncol， 2021， 11： 611118.
［44］ Holster JJ，El Hassnaoui M，Franssen S，et al. Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma： a systematic review and meta-analysis［J］. Ann Surg Oncol， 2022， 29： 5528-5538.
［45］ Ferrucci PF， Cocorocchio E， Bonomo G， et al. A new option for the treatment of intrahepatic cholangiocarcinoma： percutaneous hepatic perfusion with CHEMOSAT delivery system［J］. Cells， 2021， 10： 70.
［46］ Vogel A，Gupta S，Zeile M，et al. Chemosaturation percutaneous hepatic perfusion： a systematic review［J］. Adv Ther， 2017， 33： 2122-2138.
［47］ Marquardt S，Kirstein MM，Brüning R，et al. Percutaneous hepatic perfusion（chemosaturation） with melphalan in patients with intrahepatic cholangiocarcinoma： European multicentre study on safety， short-term effects and survival［J］. Eur Radiol， 2019， 29： 1882-1892.
［48］ Lauterio A，de Carlis R，Centonze L，et al. Current surgical mana-gement of peri-hilar and intra-hepatic cholangiocarcinoma［J］. Cancers（Basel）， 2021， 13： 3657.
［49］ Onishi Y，Isoda H，Ohno T，et al. Future liver remnant hypertrophy rate in portal vein embolization before left trisectionectomy： a retrospective cohort study［J］. Abdom Radiol（NY）， 2022， 47： 878-884.
［50］ 李书沛，余晨曦，来凤勇，等． 不可手术切除的肝内胆管细胞癌局部治疗进展［J］． 肝癌电子杂志， 2020， 7：44-47．
［51］ Schnapauff D，Denecke T，Grieser C，et al. Computed tomography-guided interstitial HDR brachytherapy（CT-HDRBT） of the liver in patients with irresectable intrahepatic cholangiocarcinoma［J］. Cardiovasc Intervent Radiol， 2012， 35： 581-587.
［52］ Boning G，Büttner L，Jonczyk M，et al. Complications of computed tomography-guided high-dose-rate brachytherapy（CT-HDRBT） and risk factors： results from more than 10 years of experience［J］. Cardiovasc Intervent Radiol， 2020， 43： 284-294.
［53］ Taggar AS， Mann P， Folkert MR， et al. A systematic review of intraluminal high dose rate brachytherapy in the management of malignant biliary tract obstruction and cholangiocarcinoma［J］. Radiother Oncol， 2021， 165： 60-74.
相似文献/References:
[1]杨智杰,高 贞,苑徳月,等.放射性125I粒子植入治疗不可手术切除软组织肉瘤9例 [J].介入放射学杂志,2018,27(11):1072.
YANG Zhijie,GAO Zhen,YUAN Deyue,et al.Radioactive 125I seed implantation for the treatment of unresectable soft tissue sarcomas： initial experience in nine cases[J].journal interventional radiology,2018,27(07):1072.
[2]张 楚,周 春,祖庆泉,等.初诊肝癌破裂出血患者的治疗策略及分析 [J].介入放射学杂志,2020,29(06):577.
ZHANG Chu,ZHOU Chun,ZU Qingquan,et al.Treatment strategies for initially inoperable ruptured hepatocellular carcinoma and analysis of curative effect[J].journal interventional radiology,2020,29(07):577.
[3]蔡智源,何朝滨,陈 尚,等.肝内胆管癌TACE治疗患者的预后因素分析[J].介入放射学杂志,2021,30(03):291.
CAI Zhiyuan,HE Chaobin,CHEN Shang,et al.Analysis of prognostic factors in patients with intrahepatic cholangiocarcinoma after receiving transcatheter arterial chemoembolization[J].journal interventional radiology,2021,30(07):291.